Brett Jorgensen
Overview
Explore the profile of Brett Jorgensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
647
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malik-Chaudhry H, Prabhakar K, Ugamraj H, Boudreau A, Buelow B, Dang K, et al.
MAbs
. 2021 Apr;
13(1):1890411.
PMID: 33818299
The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been...
2.
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Trinklein N, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, et al.
MAbs
. 2019 Jan;
11(4):639-652.
PMID: 30698484
T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing activity in humans, but cytokine release-related toxicities have affected their clinical utility. The use of novel anti-CD3 binding domains with more...
3.
Clarke S, Ma B, Trinklein N, Schellenberger U, Osborn M, Ouisse L, et al.
Front Immunol
. 2019 Jan;
9:3037.
PMID: 30666250
Heavy chain-only antibodies (HCAbs) do not associate with light chains and their V regions are functional as single domains, forming the smallest active antibody fragment. These V regions are ideal...
4.
Harris K, Force Aldred S, Davison L, Ogana H, Boudreau A, Bruggemann M, et al.
Front Immunol
. 2018 May;
9:889.
PMID: 29740455
We created a novel transgenic rat that expresses human antibodies comprising a diverse repertoire of heavy chains with a single common rearranged kappa light chain (IgKV3-15-JK1). This fixed light chain...
5.
Chan I, Van Hoof D, Abramova M, Bilardello M, Mar E, Jorgensen B, et al.
PLoS One
. 2016 Jun;
11(6):e0156229.
PMID: 27299860
Interleukin-10 (IL-10) is a multifunctional cytokine that exerts potent context specific immunostimulatory and immunosuppressive effects. We have investigated the mechanism by which PEGylated rIL-10 regulates plasma cholesterol in mice and...
6.
Marshall D, Lyman S, McCauley S, Kovalenko M, Spangler R, Liu C, et al.
PLoS One
. 2015 May;
10(5):e0127063.
PMID: 25961845
Expression of matrix metalloproteinase 9 (MMP9) is elevated in a variety of inflammatory and oncology indications, including ulcerative colitis and colorectal cancer. MMP9 is a downstream effector and an upstream...
7.
Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez H, Oyasu M, et al.
Nat Med
. 2010 Sep;
16(9):1009-17.
PMID: 20818376
We have identified a new role for the matrix enzyme lysyl oxidase-like-2 (LOXL2) in the creation and maintenance of the pathologic microenvironment of cancer and fibrotic disease. Our analysis of...
8.
Jin P, Zhang J, Beryt M, Turin L, Brdlik C, Feng Y, et al.
Mol Med
. 2008 Dec;
15(1-2):11-20.
PMID: 19048033
The human epidermal growth factor (EGF) receptor (HER) family members cooperate in malignancy. Of this family, HER2 does not bind growth factors and HER3 does not encode an active tyrosine...
9.
Sarup J, Jin P, Turin L, Bai X, Beryt M, Brdlik C, et al.
Mol Cancer Ther
. 2008 Oct;
7(10):3223-36.
PMID: 18852126
All four members of the human epidermal growth factor (EGF) receptor (HER) family are implicated in human cancers. Although efficacious in a subset of patients, resistance to single-targeted anti-HER therapy...
10.
Jin P, Zhang J, Sumariwalla P, Ni I, Jorgensen B, Crawford D, et al.
Arthritis Res Ther
. 2008 Jul;
10(4):R73.
PMID: 18593464
Introduction: Despite the advent of biological therapies for the treatment of rheumatoid arthritis, there is a compelling need to develop alternative therapeutic targets for nonresponders to existing treatments. Soluble receptors...